EX-10.39.1



 






CONFIDENTIAL




Exhibit 10.39.1




FIRST AMENDMENT TO THE MASTER DEVELOPMENT AND

TOLL MANUFACTURING AGREEMENT

BETWEEN ENDO PHARMACEUTICALS INC.

AND NOVARTIS CONSUMER HEALTH, INC.

 

 

 

 

 


The confidential portions of this exhibit have been filed separately with the
Securities and Exchange Commission pursuant to a confidential treatment request in
accordance with Rule 24b-2 of the Securities and Exchange Act of 1934, as amended.
REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN ***.




 









 





CONFIDENTIAL



This First Amendment to the Master Development and Toll Manufacturing Agreement by and between
Endo Pharmaceuticals Inc. (“Endo”) and Novartis Consumer Health, Inc. (“Novartis”) is effective as
of February 1, 2003 (this “Amendment”).



WHEREAS, Endo and Novartis entered into an agreement dated May 3, 2001 (the “Agreement”), whereby
Novartis agreed to perform certain Services on behalf of Endo as set forth therein; and



WHEREAS, Endo and Novartis desire to incorporate additional Products into such Agreement.
Therefore, the Agreement shall be amended as set forth below.



NOW THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged,
the parties hereto agree as follows:





	1.	 	Unless set forth herein, the capitalized terms contained in this Amendment shall have the
meanings set forth in the Agreement.
	 
	2.	 	ANNEX A shall be amended and restated in its entirety with the Annex A attached hereto and
made a part hereof in its entirety.
	 
	3.	 	ANNEX B shall be amended and restated in its entirety with the Annex B attached hereto and
made a part hereof in its entirety.
	 
	4.	 	ANNEX C shall be amended and restated in its entirety with the Annex C attached hereto and
made a part hereof in its entirety.
	 
	5.	 	Except as expressly provided herein, all other terms, provisions, conditions and covenants
contained in the Agreement shall remain in full force and effect.




IN WITNESS WHEREOF, Endo and Novartis have executed this Amendment as of the day and year first
written above.




	 	 	 
	ENDO PHARMACEUTICALS INC.

	 	NOVARTIS CONSUMER HEALTH, INC.
	 
	 	 
	By:  /s/ Peter Lankau 

	 	By: /s/ John McKenna
	     Peter Lankau

	 	Name: John McKenna
	     President & Chief Operating Officer

	 	Title: CFO, Business Unit






2 of 8









 





CONFIDENTIAL




ANNEX A

TO

MASTER DEVELOPMENT AND TOLL MANUFACTURING

AGREEMENT




PRODUCTS




	 	 	 	 	 	 	 	 	 
	NDC	 	 	Product Description	 	 	Batch Size
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**






3 of 8









 





CONFIDENTIAL




	 	 	 	 	 	 	 	 	 
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**






4 of 8









 





CONFIDENTIAL




ANNEX B

MASTER DEVELOPMENT AND TOLL MANUFACTURING

AGREEMENT




PRICING FOR PRODUCTS




	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	Price Per
	NDC	 	 	Description	 	 	Bottle
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**






5 of 8









 





CONFIDENTIAL




	 	 	 	 	 	 	 	 	 
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**






6 of 8









 





CONFIDENTIAL




	 	 	 	 	 	 	 	 	 
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**
	***
	 	 	*	**	 	 	*	**






7 of 8









 





CONFIDENTIAL




ANNEX C

TO

MASTER DEVELOPMENT AND TOLL MANUFACTURING

AGREEMENT




SPECIFICATIONS




***





8 of 8